Get the Stockscreener App
11.58
6.93%
0.75
Pre-market:
11.73
0.15
+1.30%
Ginkgo Bioworks Holdings Inc stock is traded at $11.58, with a volume of 1.50M.
It is up +6.93% in the last 24 hours and up +14.88% over the past month.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.
See More
Previous Close:
$10.83
Open:
$10.99
24h Volume:
1.50M
Relative Volume:
1.19
Market Cap:
$665.61M
Revenue:
$217.11M
Net Income/Loss:
$-651.19M
P/E Ratio:
-0.8915
EPS:
-12.99
Net Cash Flow:
$-387.26M
1W Performance:
+35.28%
1M Performance:
+14.88%
6M Performance:
+3.39%
1Y Performance:
-76.07%
1-Day Range:
$10.97
$12.33
1-Week Range:
$9.01
$12.33
52-Week Range:
$5.26
$64.40
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Name
Ginkgo Bioworks Holdings Inc
Sector
Industry
Phone
(877) 442-5362
Address
27 DRYDOCK AVENUE, BOSTON
Compare DNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
11.58 | 665.61M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-24 | Downgrade | BTIG Research | Neutral → Sell |
| May-10-24 | Downgrade | William Blair | Mkt Perform → Underperform |
| Nov-14-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-09-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-02-23 | Downgrade | Goldman | Neutral → Sell |
| May-11-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-29-22 | Initiated | Berenberg | Buy |
| Oct-04-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Feb-23-22 | Initiated | Goldman | Neutral |
| Feb-01-22 | Initiated | BofA Securities | Neutral |
| Jan-28-22 | Initiated | BofA Securities | Buy |
| Jan-07-22 | Initiated | BTIG Research | Buy |
| Nov-29-21 | Initiated | Jefferies | Buy |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Oct-12-21 | Initiated | William Blair | Outperform |
| Sep-20-21 | Initiated | HSBC Securities | Buy |
View All
Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News
SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development - Marketscreener.com
Ginkgo Bioworks (NYSE:DNA) Trading 9.1% HigherStill a Buy? - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Shares Gap UpStill a Buy? - MarketBeat
DNAGinkgo Bioworks Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors - PR Newswire
Ginkgo Bioworks Partners with Astellas' Universal Cells to Advance Cancer Cell Therapy Innovation - StockTitan
Ginkgo Bioworks (NYSE:DNA) Stock Price Down 9.1%What's Next? - MarketBeat
(DNA) On The My Stocks Page - Stock Traders Daily
Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire
Barclays PLC Trims Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks officer sells stock for $3,796 By Investing.com - Investing.com Canada
Ginkgo Bioworks officer sells stock for $3,796 - Investing.com India
Ginkgo Bioworks (NYSE:DNA) Trading 6.5% HigherHere's Why - MarketBeat
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Geode Capital Management LLC Trims Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by State Street Corp - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Trading Up 6.4%Here's Why - MarketBeat
(DNA) Trading Advice - Stock Traders Daily
Ginkgo Bioworks (NYSE:DNA) Stock Price Down 7.9%Here's Why - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Shares Gap DownTime to Sell? - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Shares Down 6.6%Here's What Happened - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 1,865,335 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Stock Price Up 4.1%What's Next? - MarketBeat
Teachers Retirement System of The State of Kentucky Cuts Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
All You Need to Know About Ginkgo Bioworks (DNA) Rating Upgrade to Buy - MSN
Ginkgo Bioworks joins project on cell-based disease treatment By Investing.com - Investing.com South Africa
Ginkgo Bioworks joins project on cell-based disease treatment - Investing.com
Ginkgo Bioworks Lands $9.4M Contract for Groundbreaking Bioelectronic Treatment Technology - StockTitan
Charles Schwab Investment Management Inc. Decreases Stock Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Investors Get Final OK Of $17.8M Settlement - Law360
Janus Henderson Group PLC Has $118,000 Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo to Pay $17.8 Million in Class Deal Over SPAC Merger, IPO - Bloomberg Law
Ginkgo Bioworks (NYSE:DNA) Trading Down 5.5%What's Next? - MarketBeat
Verition Fund Management LLC Takes Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Lowers Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
BNP Paribas Financial Markets Makes New Investment in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Long Term Trading Analysis for (DNA) - Stock Traders Daily
279,954 Shares in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Purchased by Jacobs Levy Equity Management Inc. - MarketBeat
Ginkgo Bioworks CFO Mark Dmytruk sells $7,146 in stock By Investing.com - Investing.com Australia
Ginkgo Bioworks executive sells $3,182 in stock - Investing.com India
Ginkgo Bioworks CFO Mark Dmytruk sells $7,146 in stock - Investing.com
Ginkgo Bioworks executive sells $3,182 in stock By Investing.com - Investing.com UK
Synthetic Biology Market Forecast: $61.6 Billion by 2029, Growing at 26.1% CAGR - GlobeNewswire Inc.
Concentric By Ginkgo and Texas A&M University Awarded USDA NIFA AFRI Grant to Conduct Genomic Animal Research to Prevent Zoonotic Disease Spillover - Marketscreener.com
Erste Asset Management GmbH Purchases Shares of 500,000 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards? - MSN
PDT Partners LLC Invests $1.20 Million in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Anchorage Capital Group L.L.C. Trims Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - MarketBeat
Ginkgo Bioworks Holdings Inc Stock (DNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):